Time-to-response in acute severe ulcerative colitis: when to continue, optimize, or stop treatment

Authors: Gisbert, Javier P; Chaparro, Maria

Source journal: Journal of Crohn's & colitis (2026-11-07)

DOI: 10.1093/ecco-jcc/jjag198

Abstract

Acute severe ulcerative colitis is an emergency in which treatment selection and timing are inseparable. This narrative review synthesizes published response trajectories and proposes treatment-specific futility windows for inpatient therapies, including intravenous corticosteroids, cyclosporine, infliximab, Janus kinase inhibitors, calcineurin-inhibitor bridging strategies, and sequential rescue. We propose that trajectory should override any protocol day. Deterioration, systemic toxicity, worsening abdominal findings, organ dysfunction, or radiologic complications should prompt immediate escalation and surgical reassessment rather than waiting for a scheduled checkpoint. Conversely, objective improvement without remission may justify cautious continuation. Therapeutic stagnation requires integrating stool frequency, bleeding, systemic features, C-reactive protein, albumin, hemoglobin, imaging, informative endoscopy, pharmacokinetic exposure when available, and surgical risk. For intravenous corticosteroids, assessment starts at admission; day 3 guides rescue preparation; if no deterioration occurs beforehand, lack of meaningful objective improvement by day 5 should prompt rescue therapy or surgery. Cyclosporine usually declares its trajectory within the first week. For infliximab, days 5-7 are the principal clinical decision window; stable patients with inadequate exposure may undergo optimization, with later reassessment reserved for partial responders. Tofacitinib and upadacitinib may act rapidly; off-label rescue evidence remains observational, and absent improvement by days 5-7 is concerning. When a calcineurin inhibitor (CNI) bridges to a maintenance biologic, acute decisions should be based on response to the CNI, not the maintenance agent. Sequential third-line rescue should be exceptional, multidisciplinary, time-limited, and never delay colectomy when deterioration or a surgical indication is present. Across therapies, reassessment must be paired with continuous surgical involvement.

Read the full text

Related topics

Related open access articles

Abstract and bibliographic data from PubMed (U.S. National Library of Medicine). Copyright of the abstract belongs to the original publisher or authors.